Cleveland Clinic is studying how blood-based biomarkers like pTau-217 perform in primary care workflows to help doctors assess cognitive impairment.
Cleveland Clinic has announced an observational implementation study examining whether blood-based biomarkers can make the Alzheimer’s diagnostic pathway more reliable and efficient after primary care identifies suspected cognitive impairment.
Researchers plan to enroll as many as 1,800 participants for this major observational implementation project. The primary biomarker for the study is the Roche Elecsys Phospho-Tau (217P) Plasma test. This specific test measures phosphorylated tau 217, or pTau-217, in blood plasma. The project will also measure pTau-181 as a secondary biomarker for additional analysis.
Cleveland Clinic currently uses the Mini-Cog instrument during eligible annual wellness visits. This standard health protocol combines a three-item recall test with a straightforward clock-drawing task. The health system reports that its facilities perform approximately 3,000 Mini-Cog tests each month. However, this current method does not clearly determine which patients should receive specialized care.
The health system notes that the existing protocol leaves questions about when confirmatory testing should be pursued. The new study intends to follow patients from the exact point that primary care identifies suspected cognitive impairment. Researchers will assess whether adding a blood test affects referral patterns and total diagnostic accuracy. They will also track the time between diagnostic milestones and the total cost of care.
The principal investigator for this implementation study is Dr. Saket Saxena, a Cleveland Clinic geriatrician. Dr. Hiba Khan, also a geriatrician, is the coinvestigator for the project. Dr. Saxena states that the project aims to move blood-based biomarker testing from the bench to the bedside. The researchers want to understand how these tests can improve real-world care for older adults.
Primary care clinics are often the settings where many people first present with memory loss or behavioral changes. Dr. Saxena notes that mild cognitive impairment and dementia are frequently missed or underdiagnosed in primary care. A known shortage of geriatricians and neurologists makes this clinical situation more difficult. Primary care clinicians need better, objective ways to determine which patients are most likely to benefit from a specialist referral.
A diagnostic blood test could be easier to deploy than cerebrospinal fluid collection or brain PET imaging. Blood collection is minimally invasive and requires less specialized medical equipment. It also requires fewer specialized personnel to manage the sample collection process. A recent clinical review characterizes high-performing plasma biomarkers like pTau-217 as practical tools for biological enrichment in symptomatic people.
These advanced plasma biomarkers are intended to serve primarily as triage tools in a clinical setting. A result could help doctors estimate whether a patient is more or less likely to have amyloid plaque and tau pathology associated with Alzheimer’s disease. This information supports clinicians in deciding who requires additional confirmation. It can help direct limited specialist time to the individuals who need it most.
Integrating this triage tool into a primary care setting could change how older adults experience the diagnostic process. Rather than waiting months for a specialist to order a PET scan, the primary care physician could evaluate a blood sample first. This could streamline the pathway for individuals seeking answers about cognitive health protection. The goal is a more efficient diagnostic pathway that moves patients toward accurate answers.
While this research is promising, the Cleveland Clinic project is observational and implementation-focused. The initial announcement does not establish that the pathway will definitely improve diagnostic accuracy or reduce overall medical costs. The planned enrollment of 1,800 participants is a study target rather than a reported result. The announcement does not provide sensitivity, positive predictive value or completed study outcomes for this specific pathway.
Roche announced FDA clearance of the Elecsys pTau217 test on August 24, 2026. This clearance applies specifically to adults aged 55 and older who already have signs, symptoms or complaints of cognitive decline. The test’s cleared purpose is to aid the identification of amyloid pathology associated with Alzheimer’s disease. The FDA clearance does not make the test an appropriate screening tool for healthy adults.
Roche clearly states that the test is not intended to be used as a stand-alone diagnostic tool. A positive biomarker result should not automatically be treated as proof that a person’s memory symptoms are caused by Alzheimer’s disease. Test results must be interpreted alongside other diagnostic tools and clinical information. The current evidence does not support ordering an Alzheimer’s blood test simply because an otherwise healthy person wants reassurance.
Cleveland Clinic notes that specialized testing will still be required before disease-modifying treatment is initiated. Patients will still need cerebrospinal fluid testing or PET imaging before starting anti-amyloid monoclonal antibody infusions. A negative or uncertain blood test result does not eliminate the need for clinical judgment. This is particularly true when symptoms are progressive, atypical or potentially caused by another medical condition.
The broader Alzheimer’s diagnostic field is steadily moving toward greater use of blood-based biomarkers. However, current clinical use remains firmly focused on people who already have cognitive symptoms or objective impairment. The Alzheimer’s Association released clinical practice guidance for blood-based biomarkers in 2025. A PCORI summary of this guidance recommends obtaining a clinical evaluation before ordering tests.
The 2025 guidance emphasizes that clinicians must interpret biomarker results within the patient's full clinical context. Cognitive impairment can have multiple contributors beyond just Alzheimer's disease. These factors include medication effects, sleep disorders, depression and vascular disease. The recommended diagnostic pathway begins with a thorough clinical assessment rather than a blood test alone.
Even if blood testing successfully reduces some unnecessary specialist referrals, the implementation could introduce new administrative challenges. Health systems must carefully manage the follow-up of borderline results and maintain equitable laboratory access. They will also need to navigate insurance coverage rules and broad clinician training. The Cleveland Clinic announcement presents these practical implementation elements as issues to study rather than resolved findings.
Understanding how a promising biomarker changes care delivery in primary care is a critical second stage of innovation. A test can perform well analytically while still creating bottlenecks in the wider care pathway. It could generate unnecessary referrals, unequal access or confusing intermediate results for patients. The current Cleveland Clinic study intends to evaluate exactly how these dynamics unfold in practice.
For an older adult noticing persistent memory and focus changes, the first practical step remains a comprehensive medical evaluation. Patients should not independently seek a blood test without consulting a clinician. You should bring a clear list of symptoms to your doctor. Be prepared to explain when the changes began, how they are changing and whether they affect daily tasks.
Tell your doctor if memory changes affect your finances, your ability to drive or your performance at work. You should also mention if these changes impact your daily medication routines or independent living. Ask the clinician to review potentially reversible or treatable contributors to cognitive decline. These can include your current medications, sleep quality and mood changes.
Your clinician should also check your hearing status and vascular health. A thorough clinical assessment remains the foundation of the biomarker pathway described in current medical guidance. If your primary care provider suspects cognitive impairment, you can ask whether blood-based biomarker testing is appropriate in your local care pathway. You should also ask what specific medical decisions the diagnostic result would actually change.
It is helpful to understand the care plan before the blood sample is ever drawn. Patients need clarity on how a positive, negative or intermediate result will dictate next steps. Ask in advance if specialist assessment, brain imaging or cerebrospinal fluid testing might still be needed after the blood test. Readers should not interpret a blood test as a prediction of whether an asymptomatic person will develop dementia.
Current cleared use is for people aged 55 and older who already have complaints of cognitive decline. A more efficient pathway could eventually help people reach appropriate dementia, Alzheimer's and cognitive protection resources sooner, but the Cleveland Clinic study is designed to determine whether that benefit occurs in practice.
Medical teams and their older patients share the responsibility of evaluating cognitive changes, and navigating new diagnostic testing protocols is clearer when FitBrainLab translates the clinical research. Confusion about what normal brain aging looks like can cause unnecessary worry, but our practical guidance helps you approach medical assessments without fear or miracle claims. Explore Resources
Follow FitBrainLab for research-led insights on memory, focus, brain aging, nutrition and mental fitness after 60. Stay connected for new articles, practical guidance and ideas for a sharper, more engaged life.
Build habits that support memory, focus and a curious, connected life.
Read the Blog
